On August 8th, Roche Pharmaceuticals' innovative anti influenza drug, Sufuda dry suspension (commonly known as Mabaroxavir dry suspension), was officially launched in China. This medicine is a strawberry flavored dry suspension designed specifically for children, mainly used to treat children under 5 to 12 years old with simple influenza A and B.

 

 

 

Parents can accurately administer medication based on their children's weight, and only need to take the medication once throughout the entire course of the disease, overcoming the long-standing problem of "guessing the dosage and breaking the medication" and poor medication compliance in children.

 

 

 

Data shows that Mabaloxavir is an innovative RNA polymerase inhibitor that has been proven effective against various influenza viruses, including oseltamivir resistant strains and in vitro active strains of avian influenza virus (H7N9, H5N1) in non clinical studies. As of now, Mabaloxavir has been approved in over 70 countries for the treatment of influenza A and B.

 

 

 

It is reported that in April 2021, Sufuda tablets (commonly known as Mabaloxavir tablets) were approved for sale in China. As a single oral medication for the treatment of influenza, it can stop virus detoxification within 24 hours, shorten the transmission period, and quickly relieve flu symptoms such as fever, providing a breakthrough treatment plan for influenza patients.

 

 

 

On December 29, 2023, Sufuda dry suspension (generic name: Mabaloxavir dry suspension) was approved for marketing by the National Medical Products Administration for the treatment of children aged 5 to 12 with simple influenza A and B.

 

 

 

The approval of the Fuda dry suspension (generic name: Mabaloxavir dry suspension) in China is expected to bring new treatment options for children under the age of 5 to 12 with simple influenza A and B.

 

 

 

Industry insiders say that children with influenza have a longer course of illness and longer detoxification time, which can easily cause transmission within schools, classes, and families. Mabaloxavir dry suspension is launched in China, and taking it once within 48 hours of onset can effectively shorten the patient's course of illness, fever duration, and detoxification time. Help the sick child return to school and study normally as soon as possible, saving social costs and medical resources.

 

 

 

Roche Pharmaceuticals has stated that its innovative anti influenza drug, Sufuda, will achieve localized production by 2024. In the future, it will rely on China's good market size, economic scale, and innovation ecology to accelerate its progress in China's innovation opportunities, continuously deepen its presence in China, and continue to help Chinese patients improve their quality of life.

 

 

 

It is reported that Roche currently has 28 products in China, covering 8 major therapeutic fields. As one of the earliest foreign-funded pharmaceutical companies to establish research and development centers in China, Roche R&D is still increasing its investment. Nowadays, Roche China Innovation Center has independent decision-making power for new drug research and early development, covering new drug research and development in the fields of immunology, oncology, and metabolic diseases, and continuously developing innovative drugs for patients.